Kurt S Bantilan

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 12

Top Topics

Machine Learning

Chronic Lymphocytic Leukemia

Top Venues

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew J Matasar, Menglei Zhu, Ashlee Joseph, Ali Castro, Erin Biggar, Gilles Andre Salles, Andrew D Zelenetz, Gottfried von Keudell
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & lymphoma (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Thais Fischer, Andy Ni, Kurt S Bantilan, Jacob D Soumerai, Anna Alperovich, Connie Lee Batlevi, Anas Younes, Andrew D Zelenetz
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leukemia & lymphoma 63 (3) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)